HC Wainwright Issues Negative Estimate for INO Earnings

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) – Stock analysts at HC Wainwright reduced their Q4 2027 earnings per share estimates for Inovio Pharmaceuticals in a research report issued on Thursday, August 13th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings per share of $0.03 for the quarter, down from their previous estimate of $0.07. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Inovio Pharmaceuticals’ current full-year earnings is ($0.99) per share.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings data on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.15.

Several other brokerages also recently commented on INO. Wall Street Zen downgraded Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, June 21st. Piper Sandler reissued an “overweight” rating and set a $4.00 target price on shares of Inovio Pharmaceuticals in a research note on Monday, August 3rd. Weiss Ratings upgraded shares of Inovio Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 29th. Jefferies Financial Group upgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “positive” rating and lifted their price objective for the company from $1.80 to $3.00 in a report on Thursday. Finally, Zacks Research upgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $3.17.

Inovio Pharmaceuticals Price Performance

Shares of NASDAQ INO opened at $0.90 on Friday. The firm has a 50-day simple moving average of $1.03 and a two-hundred day simple moving average of $1.30. Inovio Pharmaceuticals has a 1 year low of $0.56 and a 1 year high of $2.98. The company has a market cap of $74.05 million, a P/E ratio of -0.99 and a beta of 1.52.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. increased its stake in Inovio Pharmaceuticals by 0.9% during the second quarter. BlackRock Inc. now owns 18,709,432 shares of the biopharmaceutical company’s stock worth $767,648,000 after purchasing an additional 167,212 shares during the period. Janus Henderson Group PLC lifted its position in shares of Inovio Pharmaceuticals by 1.3% during the fourth quarter. Janus Henderson Group PLC now owns 3,308,406 shares of the biopharmaceutical company’s stock worth $5,773,000 after purchasing an additional 42,146 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Inovio Pharmaceuticals by 35.0% in the third quarter. Vanguard Group Inc. now owns 2,712,872 shares of the biopharmaceutical company’s stock valued at $6,348,000 after purchasing an additional 703,727 shares during the period. Millennium Management LLC boosted its stake in shares of Inovio Pharmaceuticals by 468.7% in the third quarter. Millennium Management LLC now owns 1,972,518 shares of the biopharmaceutical company’s stock valued at $4,616,000 after purchasing an additional 1,625,653 shares during the period. Finally, Eversept Partners LP acquired a new position in shares of Inovio Pharmaceuticals in the first quarter valued at approximately $1,802,000. 26.79% of the stock is currently owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.